secwatch.observer — SEC 8-K summary
======================================

Issuer:     Metagenomi Therapeutics, Inc. (MGX)
CIK:        0001785279
Form:       8-K
Filed at:   2026-05-11T20:09:09+00:00
Accession:  0001193125-26-216763
Event type: earnings
Sentiment:  neutral
Materiality: 0.35
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Metagenomi reports $140.2M cash; MGX-001 IND on track for Q4 2026
-----------------------------------------------------------------

- Cash, equivalents and marketable securities of $140.2M at March 31, 2026; runway through Q4 2027.
- MGX-001 for hemophilia A: regulatory submission including IND planned for Q4 2026, first-in-human trials in 2027.
- Kapil Saxena, MD, appointed to lead clinical development for MGX-001; prior roles at Autolus, Bayer, Daiichi Sankyo.
- R&D expenses $19.3M in Q1 2026 (vs $25.1M Q1 2025); G&A $6.5M (vs $6.8M).
- Nature publication on compact CRISPR nuclease MG119-28 with enhanced editing efficiency.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785279/000119312526216763/0001193125-26-216763-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785279/000119312526216763/mgx-20260511.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-216763

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer